^
Association details:
| Biomarker: | SF3B1 K700E |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug Class: | Hypomethylating agent |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3121 Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes
Published date:
11/04/2020
Excerpt:
Majority were treated with HMA [16/17 (94%) K700E; 15/19 (79%) non-K700, 217/ 277 (78%) SF3B1wt]. SF3B1mut had better OS than SF3B1wt in all MDS (NR vs. 25.2 months, p=0.0003; fig 1D), low-grade MDS (NR vs. 41.3 months, p=0.0015; fig 1E) and MDS-RS (NR vs. 22.3 months, p=0.0004; fig 1F).
